natgillin/translations-raw huggingface dataset:
On background therapy of metformin 1,500 mg daily (with or without sulphonylurea), Eperzan 30 mg SC weekly (with optional uptitration to 50 mg weekly) was compared to insulin glargine (started at 10 units and titrated weekly per prescribing information).
Na podlagi osnovnega zdravljenja s  1.500 mg metformina na dan (s sulfonilsečnino ali brez nje) so zdravilo Eperzan 30 mg subkutano na teden (s fakultativnim zvišanjem na 50 mg na teden) primerjali z insulinom glarginom (uvedenim z odmerkom 10 enot in titriranim tedensko v skladu z informacijami za predpisovanje).
On background therapy of metformin 1,500 mg daily plus glimepiride 4 mg daily, Eperzan 30 mg SC weekly (with optional uptitration to 50 mg weekly after a minimum of 4 weeks) was compared to placebo or pioglitazone 30 mg daily (with optional titration to 45 mg/day).
Na podlagi osnovnega zdravljenja s  1.500 mg metformina na dan + 4 mg glimepirida na dan so 30 mg zdravila Eperzan subkutano na teden (s fakultativnim zvišanjem na 50 mg na teden po najmanj 4 tednih) primerjali s placebom ali 30 mg pioglitazona na dan (s fakultativnim titriranjem na 45 mg na dan).
On background therapy of metformin 1,500 mg daily, Eperzan 30 mg SC weekly (with optional uptitration to 50 mg weekly after a minimum of 4 weeks) was compared to sitagliptin 100 mg daily, glimepiride 2 mg daily (with optional titration to 4 mg daily), or placebo.
Na podlagi osnovnega zdravljenja z  1.500 mg metformina na dan so 30 mg zdravila Eperzan subkutano na teden (s fakultativnim zvišanjem na 50 mg na teden po najmanj 4 tednih) primerjali s 100 mg sitagliptina na dan, 2 mg glimepirida na dan (s fakultativnim titriranjem na 4 mg na dan) ali placebom.
on clinical status during or
prememba odmerka
On combining the data from phase III monotherapy and adjunctive LUMIGAN 0.3 mg/ml eye drops, solution usage, the most frequently reported treatment-related adverse events were: growth of eyelashes in up to 45% in the first year with the incidence of new reports decreasing to 7% at 2 years and 2% at 3 years, conjunctival hyperaemia (mostly trace to mild and thought to be of a non- inflammatory nature) in up to 44% in the first year with the incidence of new reports decreasing to 13% at 2 years and 12% at 3 years and ocular pruritus in up to 14% of patients in the first year with the incidence of new reports decreasing to 3% at 2 years and 0% at 3 years.
S kombinacijo podatkov iz III. faze monoterapije in adjuvantne terapije z zdravilom LUMIGAN 0,3 mg/ml kapljice za oko, raztopina, so bila najpogostejša poročila o neželenih učinkih, kot posledica zdravljenja: rast trepalnic pri do 45 % bolnikov v prvem letu, z upadom števila novih poročil na 7 % pri 2 letih in 2 % pri 3 letih, hiperemija veznice (najpogosteje komaj opazna do blaga in domnevno nevnetnega izvora) pri do 44 % bolnikov v prvem letu, z upadom števila novih poročil na 13 % pri 2 letih in na 12 % pri 3 letih in okularni puritus pri do 14 % bolnikov v prvem letu, z upadom števila novih poročil na 3 % pri 2 letih in 0 % pri 3 letih.
on CYP 3A4 and interactions are not expected with protease inhibitors.
Priporočena sta pravastatin ali fluvastatin, ker njun metabolizem ne temelji na CYP 3A4 in interakcije s zaviralci proteaz niso pričakovane.
On Day 1 of next cycle, continue G-CSF as needed and maintain dose of melphalan if neutropenia was the only DLT.
1. dan naslednjega cikla nadaljujte z G-CSF po potrebi in vzdržujte odmerek melfalana, če je bila nevtropenija edina DLT.
On Day 1 of next cycle, continue G-CSF as needed and maintain dose of melphalan if neutropenia was the only Dose Limiting Toxicity (DLT).
1. dan naslednjega cikla nadaljujte z G-CSF po potrebi in vzdržujte odmerek melfalana, če je bila nevtropenija edina DLT.
On Day 1 of your first cycle, you will be given part of your first Gazyvaro dose of 100 milligrams (mg) very slowly.
Prvi dan prvega ciklusa boste zelo počasi dobili del prvega odmerka zdravila Gazyvaro, ki znaša 100 miligramov (mg).
On day 1 you will be given one rituximab infusion
1. dan boste prejeli eno infuzijo rituksimaba
On Day 1, C1 hr was comparable and C24 hr modestly elevated (36 %) in these neonates and infants relative to adults.
Prvi dan je bila C1 h pri teh novorojenčkih in dojenčkih primerljiva, C24 h pa zmerno večja (36 %) v primerjavi z odraslimi.
on day 1, possibly repeated once
prvi dan, možna ponovitev enkrat
on day 1, possibly repeated once within 3 days
razdeljeno na več odmerkov v
On Day 15 (Week 3), take off the used patch
15. dan (3. teden) odstranite uporabljeni obliž.
On Day 3, mean Cmax values were approximately 3-fold and 4-fold higher with the therapeutic and supra-therapeutic doses, respectively, relative to the mean Cmax observed at steady state with the therapeutic dose administered to HIV patients.
Na dan 3 je bila povprečna vrednosti Cmax približno 3-krat višja pri terapevtskem odmerjanju, približno 4-krat višja pa pri supraterapevtskem odmerjanju glede na povprečno vrednost Cmax, ki so jo opazili pri terapevtskih odmerkih, danih bolnikom z virusom HIV v stanju dinamičnega ravnovesja.
On Day 3, the upper 1-sided 95% confidence interval of the maximum mean difference in pre-dose baseline-corrected QTcS (study specific heart rate corrected QT) between the active drug and placebo arms was > 10 msec for the two ritonavir-boosted Invirase treatment groups (see results in Table 3).
Na tretji dan je bil zgornji enostranski 95 % interval zaupanja najvišje povprečne razlike v intervalu QTcS, popravljenem glede na stanje pred odmerjanjem (za študijo specifični interval QT, popravljen na srčni utrip) za zdravilno učinkovino in placebo > 10 msek za skupini, ki se zdravita z zdravilom Invirase s podporno terapijo z ritonavirjem (glejte rezultate v preglednici 3).
On Day 3, those randomized to receive buprenorphine/naloxone were switched to the combination tablet.
Tretji dan so osebe, ki so bile naključno razporejene v skupino za prejemanje buprenorfina/naloksona, prešle na tablete s kombinacijo učinkovin.
On day 7, 8, or 9 you will be given one rituximab infusion, followed by one Zevalin infusion shortly afterwards (within 4 hours).
7., 8. ali 9 dan boste prejeli eno infuzijo rituksimaba, ki ji bo kmalu zatem sledila ena infuzija zdravila Zevalin (v roku 4 ur).
On Days 2 and 3, patients in the control group received 8 mg oral ondansetron every 12 hours.
2. in 3. dan so bolniki v kontrolni skupini prejeli 8 mg ondansetrona peroralno vsakih 12 ur.
On Days 2 and 3, patients in the fosaprepitant group received placebo for ondansetron every 12 hours.
2. in 3. dan so bolniki v skupini s fosaprepitantom prejeli placebo namesto ondansetrona vsakih 12 ur.
On Demand Treatment
Meðferð eftir þörfum
On dose of 0.5 ml contains:
En odmerek po 0,5 ml vsebuje:
On each left hand page you’ll find useful tips and explanations on how to get the best from your medicine.
Na vsaki levi strani najdete koristne nasvete in razlage o najboljši uporabi svojega zdravila.
On first use, the bottle adapter must be fitted into the neck of the bottle.
Pri prvi uporabi mora biti nastavek nameščen na vrat plastenke.
On hearing the second ‘click’ (or, if you do not hear a second ‘click’, after 10 seconds have passed), your injection will be complete (see Diagram 6).
Ko zaslišite drugi klik (ali, če ne zaslišite drugega klika, ko bo minilo 10 sekund), bo injiciranje končano (glejte sliko 6).
on historical data, a decrease in etravirine
s starejšimi podatki, lahko pričakujemo
On initiation of antiviral therapy the platelet count may fall, so immediate eltrombopag dose reductions should be avoided.
- Po uvedbi protivirusnega zdravljenja lahko število trombocitov pade, vendar se je potrebno izogniti nenadni prilagoditvi odmerka eltrombopaga.
On initiation of carbamazepine, the dose of TREVICTA should be re-evaluated and increased if necessary.
Ob uvajanju karbamazepina je treba odmerek zdravila TREVICTA ponovno oceniti in ga po potrebi zvečati.
On initiation of carbamazepine, the dose of Xeplion should be re-evaluated and increased if necessary.
Ob uvajanju karbamazepina je treba odmerek zdravila Xeplion ponovno oceniti in ga po potrebi zvečati.
On initiation of ixekizumab therapy in patients being treated with these types of medicinal products, therapeutic monitoring should be considered.
Ob uvedbi zdravljenja z iksekizumabom je treba pri bolnikih, ki prejemajo tovrstna zdravila, razmisliti o terapevtskem spremljanju zdravljenja.
On initiation of secukinumab therapy in patients being treated with these types of medicinal products, therapeutic monitoring should be considered.
Pri bolnikih, ki prejemajo tovrstna zdravila, je ob uvedbi sekukinumaba treba razmisliti o terapevtskem spremljanju uporabe zdravila.
on its own (monotherapy) in patients whose diabetes is not sufficiently controlled by diet and exercise and who cannot take metformin;
amostojno (zdravljenje z enim zdravilom) pri bolnikih, pri katerih sladkorna bolezen ni zadostno urejena s prehrano in telesno vadbo ter ki ne morejo jemati metformina.
on its own (monotherapy) in patients whose diabetes is not sufficiently controlled by diet and exercise and who cannot take metformin;
amostojno (zdravljenje z enim zdravilom) pri bolnikih, pri katerih sladkorna bolezen ni zadostno urejena s prehrano in telesno vadbo ter ki ne morejo jemati metformina;
on its own if your blood sugar is not properly controlled by diet and exercise alone, and you can’t take metformin (another diabetes medicine)
kot samostojno zdravljenje, če krvnega sladkorja nimate ustrezno urejenega samo z dieto in telesno dejavnostjo ter ne morete jemati metformina (drugo zdravilo za zdravljenje sladkorne bolezni)
on its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy, to treat a certain form of epilepsy.
amostojno za zdravljenje pri odraslih in mladostnikih od 16. leta starosti z na novo diagnosticirano epilepsijo, za zdravljenje določene oblike epilepsije.
on its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy, to treat a certain form of epilepsy.
amostojno za zdravljenje pri odraslih in mladostnikih, od 16. leta starosti, z na novo diagnosticirano epilepsijo, za zdravljenje določene oblike epilepsije.
on its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy, to treat a certain form of epilepsy.
za samostojno zdravljenje pri odraslih in mladostnikih od 16. leta starosti z na novo diagnosticirano epilepsijo, za zdravljenje določene oblike epilepsije.
on its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy, to treat a certain form of epilepsy.
za samostojno zdravljenje pri odraslih in mladostnikih od 16. leta starosti z na novo diagnosticirano epilepsijo, za zdravljenje za zdravljenje določene oblike epilepsije.
on its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy, to treat a certain form of epilepsy.
za samostojno zdravljenje pri odraslih in mladostnikih od 16. leta starosti, z na novo diagnosticirano epilepsijo, za zdravljenje določene oblike epilepsije.
on its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy, to treat a certain form of epilepsy.
za samostojno zdravljenje pri odraslih in mladostnikih, od 16. leta starosti, z na novo diagnosticirano epilepsijo, za zdravljenje določene oblike epilepsije.
on its own in patients for whom metformin (another diabetes medicine) is not suitable;
kot samostojno zdravilo pri bolnikih, za katere metformin (drugo zdravilo za zdravljenje sladkorne bolezni) ni primeren;
on its own in patients for whom metformin (another diabetes medicine) is not suitable;
kot samostojno zdravilo pri bolnikih, za katere metformin (drugo zdravilo za zdravljenje sladkorne bolezni) ni primerno;
on its own when exercise and diet are not providing adequate control of blood glucose and when use of metformin (another medicine for type 2 diabetes) is not recommended; as an ‘add-on’ to other diabetes medicines and/or basal insulin, when these medicines together with exercise and diet are not providing adequate control of blood glucose.
amostojno, kadar telesna vadba in dieta ne zadostujeta za zadosten nadzor nad ravnmi glukoze v krvi in kadar metformin (drugo zdravilo za zdravljenje sladkorne bolezni tipa 2) ni priporočljiv; kot dodatek k drugim zdravilom za zdravljenje sladkorne bolezni in/ali bazalnemu insulinu, kadar ta zdravila skupaj s telesno vadbo in dieto ne zagotavljajo zadostnega nadzora nad ravnmi glukoze v krvi.
on its own, in patients who are not satisfactorily controlled on diet and exercise and in whom metformin (a diabetes medicine) is not suitable; in combination with metformin or a PPAR-gamma agonist (a type of diabetes medicine) such as a thiazolidinedione, in patients who are not satisfactorily controlled on metformin or the PPAR- gamma agonist used on its own;
kot samostojno zdravilo pri bolnikih, katerih bolezen samo z dieto in telesno vadbo ni zadovoljivo nadzorovana in pri katerih metformin (zdravilo za zdravljenje sladkorne bolezni) ni primeren; v kombinaciji z metforminom ali agonistom PPAR–gama (vrsto zdravila proti sladkorni bolezni), kot je tiazolidinedion, pri bolnikih, katerih bolezen samo z metforminom ali agonistom PPAR-gama ni zadovoljivo nadzorovana;
on its own, in patients who are not satisfactorily controlled on diet and exercise and in whom metformin (an antidiabetes medicine) is not suitable; in combination with metformin or a PPAR-gamma agonist (a type of antidiabetes medicine) such as a thiazolidinedione, in patients who are not satisfactorily controlled on metformin or the PPAR- gamma agonist used on its own;
amostojno pri bolnikih, katerih bolezen samo z dieto in telesno vadbo ni zadovoljivo nadzorovana in pri katerih metformin (zdravilo za zdravljenje sladkorne bolezni) ni primeren; v kombinaciji z metforminom ali agonistom PPAR–gama (vrsto zdravila proti sladkorni bolezni), kot je tiazolidinedion, pri bolnikih, katerih bolezen samo z metforminom ali agonistom PPAR-gama ni zadovoljivo nadzorovana;
On liver microsomes, pitolisant does not significantly inhibit the activities of the cytochromes CYP1A2, CYP2C9, CYP2C19, CYP2C8, CYP2B6, CYP2E1 or CYP3A4 and of uridine diphosphate glucuronosyl transferases isoforms UGT1A1, UGT1A4, UGT1A6, UGT1A9 and UGT2B7 up to the concentration of 13.3 µM, a level considerably higher than the levels achieved with therapeutic dose.
Kar zadeva jetrne mikrosome, pitolizant bistveno ne zavira delovanja citokromov CYP1A2, CYP2C9, CYP2C19, CYP2C8, CYP2B6, CYP2E1 in CYP3A4 ter izooblik uridin difosfat glukuronoziltransferaz UGT1A1, UGT1A4, UGT1A6, UGT1A9 in UGT2B7 pri koncentracijah do 13,3 µM, kar je bistveno večja koncentracija od tistih, ki se pojavijo pri terapevtskih odmerkih.
On occasions when administration at the same time of the day is not possible, Tresiba allows for flexibility in the timing of insulin administration (see section 5.1).
V primerih, ko apliciranje ob istem času dneva ni mogoče, zdravilo Tresiba omogoča prilagodljivost v času apliciranja insulina (glejte poglavje 5.1).
On occasions when it is not possible to take Tresiba at the same time of the day, it can be taken at a different time of day.
V primerih, ko uporaba zdravila Tresiba ob običajnem času ni mogoča, lahko uporabite zdravilo Tresiba ob drugem času dneva.
On our example schedule, each area is split again into 6 injection sites (which adds up to 48 injection sites all together), left and right: upper, middle and lower part of each area.
V našem razporedu je vsak predel razdeljen na 6 mest injiciranja (kar skupno tvori 48 mest injiciranja): na zgornji, srednji in spodnji del na levi in desni strani.
On rare occasions these muscle disorders have been serious. (See section 4 Possible side effects)
V redkih primerih so bile te mišične motnje resne (glejte poglavje 4 Možni neželeni učinki).
On rare occasions these muscle problems have been serious causing muscle degeneration (rhabdomyolysis).
Redko so bile te mišične težave resne in so povzročile razgradnjo mišičnih vlaken (rabdomioliza).
On rare occasions, a specific and severe type of lymphoma called hepatosplenic T-cell lymphoma has been observed in patients taking other TNF-blockers.
V redkih primerih so pri bolnikih, ki so jemali druge zaviralce TNF, opazili določeno hudo obliko limfoma, imenovanega jetrnovranični T-celični limfom.
On rare occasions, a specific and severe type of lymphoma, has been observed in patients taking Humira.
V redkih primerih so pri bolnikih, ki dobivajo zdravilo Humira, opazili specifično in resno obliko limfoma.
On rare occasions, an uncommon and severe type of lymphoma, has been seen in patients taking Humira.
V redkih primerih so pri bolnikih, ki dobivajo zdravilo Humira, opazili redko in resno obliko limfoma.
On rare occasions, fever has been observed.
Ob redkih priložnostih so opažali povišano telesno temperaturo.
On rare occasions, people treated with TNF blockers have developed lupus.
V redkih primerih se je namreč pri osebah, zdravljenih z zaviralci TNF, pojavil lupus.
On rare occasions, reports of change of behaviour such as polyphagia, or very rarely reports of aggression associated with food and feeding have been observed in Slentrol-treated dogs.
V redkih primerih so pri psih, ki so prejemali Slentrol, poročali o spremembah v obnašanju, kot je polifagija, v zelo redkih primerih, pa o opaženi agresiji, povezani s hrano in hranjenjem.
On reconstitution as directed, 1 ml of the resulting dispersion contains 8 µl sulphur hexafluoride in the microbubbles, equivalent to 45 microgrammes.
Po pripravi po navodilih vsebuje 1 ml pripravljene disperzije 8 µl žveplovega heksafluorida v obliki mikromehurčkov, kar ustreza 45 mikrogramom.
On removal of an Livensa patch, testosterone serum concentrations return to near baseline values within 12 hours due to its short terminal exponential half-life (approximately 2 hours).
Po odstranitvi obliža Livensa se zaradi kratke končne eksponentne razpolovne dobe (približno 2 uri) koncentracije testosterona v serumu v 12 urah vrnejo skoraj na izhodiščno vrednost.
On repeat dosing, maximum plasma concentrations of idebenone are reached on average within 1 hour (median 0.67 h range: 0.33-2.00 h).
Pri večkratnem odmerjanju se največje koncentracije idebenona v plazmi dosežejo v povprečno 1 uri (mediana 0,67 h, razpon: 0,33-2,00 h).
on skin WAIT
na kožo POČAKAJTE
On the balance of the available evidence the CHMP decided that Mysimba’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Na podlagi razpoložljivih dokazov je zato zaključil, da so koristi zdravila Mysimba večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
On the basis of current pharmacodynamic data amprenavir should be used in combination with at least two other antiretrovirals.
Na osnovi razpoložljivih farmakodinamičnih podatkov je potrebno amprenavir uporabljati v kombinaciji s še najmanj dvema drugima protiretrovirusnima zdraviloma.
On the basis of pharmacokinetics, no dose adjustment is necessary in patients with mild to moderate renal impairment (creatinine clearance of 30-80 ml/min.).
Glede na farmakokinetiko, bolnikom z blago do zmerno okvaro ledvic (očistek kreatinina 30–80 ml/min), odmerka ni treba prilagoditi.
On the basis of Phase II and Phase III clinical trial data, a population exposure-response relationship was established between average plasma concentration of certolizumab pegol during a dosing interval (Cavg) and efficacy (ACR 20 responder definition).
Farmakokinetična/farmakodinamična populacijska analiza podatkov kliničnih študij II. in III. faze je pokazala razmerje med izpostavljenostjo in odzivom s primerjanjem povprečne plazemske koncentracije certolizumab pegola med posameznimi odmerki (Cavg) in učinkovitostjo (definicija bolnika z odzivom ACR 20).
On the basis of reported adverse drug reactions, Cubicin is presumed to be unlikely to produce an effect on the ability to drive or use machinery.
Na osnovi poročanih neželenih učinkov sklepamo, da je malo verjetno, da bi zdravilo Cubicin vplivalo na sposobnost vožnje in upravljanja s stroji.
On the basis of reported adverse reactions, Empliciti is not expected to influence the ability to drive or use machines.
Na podlagi sporočenih neželenih učinkov se ne predvideva, da bi zdravilo Empliciti vplivalo na sposobnost vožnje in upravljanja s stroji.
On the basis of reported adverse reactions, Perjeta is not expected to influence the ability to drive or use machines.
Na osnovi poročil o neželenih učinkih ne pričakujemo, da bi zdravilo Perjeta imelo vpliv na sposobnost vožnje in upravljanja s stroji.
On the basis of serological data, antibodies are present at 21 days post vaccination.
Na osnovi seroloških podatkov so protitelesa prisotna 21 dni po cepljenju.
On the basis of standardized incidence ratios, the incidence of malignancies appears to be similar to that previously reported in patients with ANCA-associated vasculitis.
Na podlagi standardiziranih incidenčnih razmerij je incidenca malignih bolezni podobna, kot je bila pred tem opisana pri bolnikih z vaskulitisom, povezanim z ANCA.
On the basis of the clinical studies, the recommended dose for patients over the age of 65 years is 20 mg per day (one 20 mg film-coated tablet once a day) as described above.
Na podlagi izsledkov kliničnih študij je priporočeni odmerek za bolnike, starejše od 65 let, 20 mg na dan (dve 10-miligramski filmsko obloženi tableti enkrat na dan), kot je opisano zgoraj.
On the basis of the clinical studies, the recommended dose for patients over the age of 65 years is 20 mg per day (two 10 mg film-coated tablets once a day) as described above.
Na podlagi izsledkov kliničnih študij je priporočeni odmerek za bolnike, starejše od 65 let, 20 mg na dan (dve 10-miligramski filmsko obloženi tableti enkrat na dan), kot je opisano zgoraj.
On the basis of the clinical studies, the recommended dose for patients over the age of 65 years is 20 mg per day (two 10 mg film-coated tablets once a day) as described above.
Na podlagi kliničnih študij je priporočen odmerek za bolnike nad 65 let starosti 20 mg na dan (dve 10 mg filmsko obloženi tableti enkrat dnevno), kot je opisano zgoraj.
On the basis of the clinical studies, the recommended dose for patients over the age of 65 years is 20 mg per day (two 10 mg film-coated tablets once a day) as described above.
Na podlagi kliničnih študij je priporočen odmerek za bolnike, starejše od 65 let, 20 mg na dan (dve 10-miligramski filmsko obloženi tableti), kot je opisano zgoraj.
On the basis of the clinical studies, the recommended dose for patients over the age of 65 years is 20 mg per day as described above.
Na podlagi kliničnih študij je priporočen odmerek za bolnike nad 65 let starosti 20 mg na dan (20 mg enkrat dnevno), kot je opisano zgoraj.
On the basis of the mechanism of action of febuxostat on XO inhibition concomitant use is not recommended.
Na podlagi poznavanja mehanizma delovanja febuksostata na zaviranje ksantinske oksidaze se sočasno jemanje ne priporoča.
On the basis of the pharmacodynamic and pharmacokinetic profile and reported adverse reactions, it is expected that Iasibon has no or negligible influence on the ability to drive and use machines
Glede na farmakodinamske in farmakokinetične lastnosti ter poročane neželene učinke pričakujemo, da zdravilo Iasibon nima ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
On the basis of the pharmacodynamic and pharmacokinetic profile and reported adverse reactions, it is expected that Iasibon has no or negligible influence on the ability to drive and use machines.
Glede na farmakodinamske in farmakokinetične lastnosti ter poročane neželene učinke pričakujemo, da zdravilo Iasibon nima ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
On the basis of the pharmacodynamic and pharmacokinetic profile and reported adverse reactions, it is expected that ibandronic acid has no or negligible influence on the ability to drive and use machines.
Glede na farmakodinamske in farmakokinetične lastnosti ter poročane neželene učinke pričakujemo, da zdravilo Ibandronska kislina Accord nima ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.